TechNavi's analysts forecast the Global Hemophilia Treatment market to grow at a CAGR of 5.5 percent over the period 2010-2014. One of the key factors contributing to this market growth is hemophilia is an inherited disorder. The Global Hemophilia Treatment market has also been witnessing the trend of home hemophilia treatment therapy. However, high cost of treatment could pose a challenge to the growth of this market.

TechNavio's report, Global Hemophilia Treatment Market 2010-2014, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hemophilia Treatment market landscape and its growth prospects in the coming years.

This report includes treatments for hemophilia A, B, and C, namely, recombinant factor VIII and coagulation factor IX, and Desmopressin (DDAVP) which stimulates the release of factor VIII and also increases the level of proteins in the blood.

Key vendors dominating this market space include Baxter Healthcare Corp., Novo Nordisk A/S, Bayer Healthcare Pharmaceuticals Inc., and Pfizer Inc.

Key questions answered in this report:
What will the market size be in 2014 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of analyst time when you purchase this report. Details provided within the report.